2025 Breast Cancer SPORE Investigators Workshop (Agenda)

Agenda

Date: June 26-27, 2025 (Please note, all times are ET)

DAY 1: (8:30 AM to 6:30 PM)

Session 1: Overview of SPOREs
8:30 – 8:40 AM	Welcome Toby Hecht, Ph.D., (TRP, DCTD, NCI) Logistics Naveena Janakiram, Ph.D., (TRP, DCTD, NCI)
8:40 – 8:50 AM	Report on current status of Breast Cancer SPORE portfolio Naveena Janakiram, Ph.D., (TRP, DCTD, NCI)
Chair: Naveena Janakiram, Ph.D., (TRP, DCTD, NCI)
8:25 – 8:35 AM	Charles Perou, Ph.D., (University of North Carolina Lineberger Comprehensive Cancer Center)
8:35 – 8:45 AM	Matthew Goetz, M.D., (Mayo Clinic)
8:45 – 8:55 AM	Kornelia Polyak, M.D., Ph.D., (Dana-Farber Harvard Cancer Center)
8:55 – 9:05 AM	Xiang Zhang, Ph.D (Baylor College of Medicine)
9:05 – 9:15 AM	Simon Powell, MD, Ph.D., (Memorial Sloan Kettering cancer Center)
9:15 – 9:25 AM	Pietenpol, MD, (Vanderbilt-Ingram Cancer center)
9:25 – 9:35 AM	Le Marchand, MD, Ph.D., (University of Hawai‘i Cancer Center)
Break – 5 minutes
Keynote/Plenary Speaker: Speaker introduction by – Matthew Goetz, M.D., (Mayo Clinic)
9:40 – 10:15 PM	Halamka, John D., M.D., M.S. (Mayo Clinic) “Driving the platform transformation of healthcare”
Q & A – 5 mins
Session 2: Understandings of tumor microenvironment and immunotherapies
Co- Chairs – Kornelia Polyak, M.D., Ph.D., and Peter Lucas, M.D., Ph.D.
10:20 – 10:40 AM	Xiang Zhang, Ph.D.– (Baylor College of Medicine) “The impact of tumor-induced systemic immunosuppression on breast cancer progression and therapeutic response”
10:40 – 11: 00 AM	Justin Balko, Pharm.D., Ph.D. – (Vanderbilt-Ingram Cancer Center) “Antigen presentation deficiencies in breast cancer”
11:00 – 11:20 AM	Peter Lucas, M.D., Ph.D. (Mayo Clinic) “p95HER2 as a driver of tumor immune suppression and therapy resistance in HER2+ breast cancer”
11:20 – 11: 50 AM	Kornelia Polyak, M.D., Ph.D., (Dana-Farber Harvard Cancer Center) “Immune escape in breast cancer”
11:50 – 12: 00 AM	Questions and discussion
12:00 – 1:00 PM	Lunch
Session 3: DNA repair and therapeutic opportunities
Co-Chairs – Simon Powell, M.D., Ph.D., and Gaorav Gupta, M.D., Ph.D.
1:00 – 1:20 PM	Geoff Shapiro, M.D., Ph.D., – (Dana-Farber Harvard Cancer Center) “Immunologic consequences of PARP inhibition in BRCA-associated breast Cancer”
1:20 – 1:40 PM	Gaorav Gupta, M.D., Ph.D., – (University of North Carolina Lineberger Comprehensive Cancer Center) "Radiation-Immunotherapy Synergy in Early-Stage Breast Cancer”
1:40 – 2:00 PM	Avantika Gupta, Ph.D. – (Memorial Sloan Kettering Cancer Center) “APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer”
2:00 – 2:20 PM	Rob Mutter, M.D. (Mayo Clinic) "Program for clinical translation of minibeam radiotherapy (MBRT)”
2:20 – 2:30 PM	Questions and discussion
Break for 10 minutes
2:40 – 3:30 PM	Working Group 1 - Novel technologies for translating bench to bedside and beyond Chair – Justin Balko, Pharm.D., Ph.D. 10 mins - Summary
Session 4: Biological and socioeconomic influences on survival
Co-Chairs: Loic Le Marchand, M.D., Ph.D., and Melissa Troester, Ph.D., M.P.H
3:40 – 4:00 PM	Deborah Collyar (Patient Advocate) “How Intricate Relationships Between Patient Advocates and SPOREs Can Improve Outcomes”
4:00 – 4:20 PM	Sonya Reid, M.D., M.P.H. - (Vanderbilt-Ingram Cancer Center) "Leveraging genomics to improve breast cancer outcomes."
4:20 – 4:40 PM	Lenora Loo, Ph.D. – (University of Hawai‘i Cancer Center) "Characterization of Biological Signatures and the Tumor Immune Microenvironment of Breast Tumors in a Multiethnic Population: The Multiethnic Cohort Study"
4:40 – 5:00 PM	Melissa Troester, Ph.D., M.P.H – (University of North Carolina Lineberger Comprehensive Cancer Center) "Scaling from Molecules to Communities: The Carolina Breast Cancer Study"
5:00 – 5:10 PM	Q & A
Session 5: Early-stage investigators
Co-Chairs – Matthew Goetz, M.D., and Nancy Lin, M.D.
5:10 – 5:20 PM	Meenakshi Anurag, Ph.D. - (Baylor College of Medicine) “Defining the functional and therapeutic impact of LIG1 depletion in triple-negative breast cancer”
5:20 – 5:30 PM	Pedram Razavi, M.D., Ph.D. – (Memorial Sloan Kettering Cancer Center) “Forecasting Outcomes and Mechanisms of Resistance to CDK4/6 Inhibitors"
5:30 – 5:40 PM	Roberto Leon-Ferre, M.D. – (Mayo Clinic) “Targeting DNMTs in TNBC"
5:40 – 5:50 PM	Ebonee Butler, Ph.D, M.P.H.– (University of North Carolina Lineberger Comprehensive Cancer Center) “Examining the Impact of Diagnostic Delay on Care Quality, Tumor Biology, and Disparities in Breast Cancer Survival and Mortality”
5:50 – 6:00 PM	Brent Ferrell, M.D. - (Vanderbilt-Ingram Cancer Center) “Modeling the impact of clonal hematopoiesis on tumor growth in breast Cancer”
6:00 – 6:10 PM	Filipa Lynce, M.D. - (Dana-Farber Harvard Cancer Center) “Macrophage targeting in BRCA associated breast cancer”
6:10 – 6:25 PM	Q & A
6:25 PM	Concluding remarks Naveena Janakiram, Ph.D., (TRP, DCTD, NCI)

DAY 2: (8:00 AM to 1:30 PM)

Session 6: Artificial intelligence and new technologies
Co-Chairs: Charles Perou, Ph.D., and Sohrab Shah, Ph.D.
8:00 – 8:20 AM	Bing Zhang, Ph.D. – (Baylor College of Medicine) "Computational Proteogenomics and Immunopeptidomics for Tumor Antigen Discovery”
8:20 – 8:40 AM	Christine Micheel, Ph.D. - (Vanderbilt Ingram Cancer Center) “Large Language Model–Assisted Chart Curation: Enhancing Breast Cancer Research and Clinical Care with AI”
8:40 – 9:00 AM	Sohrab Shah, Ph.D. – (Memorial Sloan Kettering Cancer Center) “AI models for digital histopathologic data in breast cancer”
9:00 – 9:20 AM	John Shepherd, Ph.D. – (University of Hawai‘i Cancer Center) “Tumor and Adiposity Characteristics Associated with Deep Learning Breast Imaging Biomarkers”
9:20 – 9:35 AM	Questions and discussion
Break for 10 minutes
9:45 – 10:45 PM	Working Group 2 - Challenges in clinical research, patient approaches, availability of resources, and opportunities for collaborations, and future directions Chair – Lisa Carey, M.D. 10 mins - Summary
Break for 10 minutes
Session 7: Novel therapeutic targets
Co-Chairs – Matthew Goetz, M.D., and Nancy Lin, M.D.
11:00 – 11:20 AM	Leif Ellisen, M.D., Ph.D.– (MGH/Dana-Farber Harvard Cancer Center) “Incorporating ADCs into novel combinations to overcome treatment Resistance”
11:20 – 11:50 AM	Benjamin Vincent, M.D. – (University of North Carolina Lineberger Comprehensive Cancer Center) "Adaptive Immunotherapy Target Discovery in Triple-Negative Breast Cancer"
11:50 – 12:10 PM	John Hawse, IV, Ph.D. (Mayo Clinic) "LMTK2: A novel determinant of endocrine resistance in ER+ breast cancer."
12:10 – 12:30 PM	Sfeir Agnel, Ph.D. (Memorial Sloan Kettering Cancer Center) "Breaking New Ground: Polθ Inhibitors as Emerging Targets in Breast Cancer Therapy"
12:30 – 12:50 PM	Gloria V Echeverria, Ph.D. – (Baylor College of Medicine) "Mitochondrial dependencies in chemo-refractory triple negative breast Cancer"
12:50 – 1: 05 PM	Questions and discussion
1:05 – 1:15 PM	Meeting Summary & Future Directions – by Matthew Goetz, M.D., and Chuck Perou, M.D.
1:15 – 1: 20 PM	Concluding remarks and adjourn. Naveena Janakiram, Ph.D.